196 related articles for article (PubMed ID: 38226882)
1. Diagnosis and Monitoring of Nonalcoholic Steatohepatitis: Current State and Future Directions.
Kadi D; Loomba R; Bashir MR
Radiology; 2024 Jan; 310(1):e222695. PubMed ID: 38226882
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.
Younossi ZM; Loomba R; Anstee QM; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Goodman ZD; Chalasani NP; Kowdley KV; George J; Lindor K
Hepatology; 2018 Jul; 68(1):349-360. PubMed ID: 29222917
[TBL] [Abstract][Full Text] [Related]
3. Current and Emerging Biomarkers and Imaging Modalities for Nonalcoholic Fatty Liver Disease: Clinical and Research Applications.
Hydes T; Brown E; Hamid A; Bateman AC; Cuthbertson DJ
Clin Ther; 2021 Sep; 43(9):1505-1522. PubMed ID: 34400007
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.
Castera L; Friedrich-Rust M; Loomba R
Gastroenterology; 2019 Apr; 156(5):1264-1281.e4. PubMed ID: 30660725
[TBL] [Abstract][Full Text] [Related]
5. Histopathological Diagnosis of Nonalcoholic Steatohepatitis (NASH).
Giashuddin S; Alawad M
Methods Mol Biol; 2022; 2455():1-18. PubMed ID: 35212981
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
Zhou JH; Cai JJ; She ZG; Li HL
World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet?
Alkhouri N; Feldstein AE
Metabolism; 2016 Aug; 65(8):1087-95. PubMed ID: 26972222
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography.
Tsai E; Lee TP
Clin Liver Dis; 2018 Feb; 22(1):73-92. PubMed ID: 29128062
[TBL] [Abstract][Full Text] [Related]
9. Role of liver biopsy in nonalcoholic fatty liver disease.
Nalbantoglu IL; Brunt EM
World J Gastroenterol; 2014 Jul; 20(27):9026-37. PubMed ID: 25083076
[TBL] [Abstract][Full Text] [Related]
10. Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments.
Ahn SB
Clin Mol Hepatol; 2023 Feb; 29(Suppl):S150-S156. PubMed ID: 36696960
[TBL] [Abstract][Full Text] [Related]
11. Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH).
Drescher HK; Weiskirchen S; Weiskirchen R
Cells; 2019 Aug; 8(8):. PubMed ID: 31394730
[TBL] [Abstract][Full Text] [Related]
12. Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis.
Shi YW; Fan JG
Clin Mol Hepatol; 2023 Feb; 29(Suppl):S228-S243. PubMed ID: 36521452
[TBL] [Abstract][Full Text] [Related]
13. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
14. Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Hannah WN; Harrison SA
Hepatology; 2016 Dec; 64(6):2234-2243. PubMed ID: 27338123
[TBL] [Abstract][Full Text] [Related]
15. Liver fibrosis markers of nonalcoholic steatohepatitis.
Enomoto H; Bando Y; Nakamura H; Nishiguchi S; Koga M
World J Gastroenterol; 2015 Jun; 21(24):7427-35. PubMed ID: 26139988
[TBL] [Abstract][Full Text] [Related]
16. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Concepts.
Papatheodoridi M; Cholongitas E
Curr Pharm Des; 2018; 24(38):4574-4586. PubMed ID: 30652642
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Imaging Modalities Against Liver Biopsy in Nonalcoholic Fatty Liver Disease: The Amsterdam NAFLD-NASH Cohort.
Troelstra MA; Witjes JJ; van Dijk AM; Mak AL; Gurney-Champion O; Runge JH; Zwirs D; Stols-Gonçalves D; Zwinderman AH; Ten Wolde M; Monajemi H; Ramsoekh S; Sinkus R; van Delden OM; Beuers UH; Verheij J; Nieuwdorp M; Nederveen AJ; Holleboom AG
J Magn Reson Imaging; 2021 Dec; 54(6):1937-1949. PubMed ID: 33991378
[TBL] [Abstract][Full Text] [Related]
19. Radiologic evaluation of nonalcoholic fatty liver disease.
Lee SS; Park SH
World J Gastroenterol; 2014 Jun; 20(23):7392-402. PubMed ID: 24966609
[TBL] [Abstract][Full Text] [Related]
20. Noninvasive Evaluation for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
Kogachi S; Noureddin M
Clin Ther; 2021 Mar; 43(3):455-472. PubMed ID: 33581876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
